

Resource Summary Report

Generated by [NIF](#) on Sep 18, 2026

EoL-1

RRID:CVCL_0258

Type: Cell Line

Proper Citation

RRID:CVCL_0258

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_0258

Proper Citation: RRID:CVCL_0258

Description: Cell line EoL-1 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Male

Disease: Chronic eosinophilic leukemia, not otherwise specified

Defining Citation: [PMID:1477652](#), [PMID:2415185](#), [PMID:8558913](#), [PMID:14630792](#), [PMID:14671638](#), [PMID:15843827](#), [PMID:16408098](#), [PMID:20164919](#), [PMID:22460905](#), [PMID:25877200](#), [PMID:26589293](#), [PMID:27397505](#), [PMID:30285677](#), [PMID:30629668](#), [PMID:30894373](#), [PMID:31068700](#), [PMID:31160637](#), [PMID:31978347](#), [PMID:35839778](#)

Comments: Population: Caucasian., Part of: LL-100 blood cancer cell line panel., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: EoL-1

Synonyms: EOL-1, EOL1, EoL-1-cell, EoL-1 cell, AML-EOL-1

Cross References: BTO:BTO_0002405, CLO:CLO_0002932, CLO:CLO_0002933, CLO:CLO_0050996, EFO:EFO_0022659, MCCL:MCC:0000149, CLDB:cl1166, ArrayExpress:E-MTAB-783, ArrayExpress:E-MTAB-2770, ArrayExpress:E-MTAB-3610, ArrayExpress:E-MTAB-7721, ArrayExpress:E-MTAB-7722, BioGRID_ORCS_Cell_line:209, BioSample:SAMN01821624, BioSample:SAMN03473158, BioSample:SAMN10988490, cancercellines:CVCL_0258,

Cell_Model_Passport:SIDM00277, ChEMBL-Cells:CHEMBL3308381, ChEMBL-Targets:CHEMBL614489, Cosmic:787428, Cosmic:798671, Cosmic:906856, Cosmic:975246, Cosmic:994180, Cosmic:999731, Cosmic:1012065, Cosmic:1278780, Cosmic:1623638, Cosmic:2131562, Cosmic-CLP:906856, DepMap:ACH-000198, DSMZ:ACC-386, DSMZCellDive:ACC-386, ECACC:94042252, EGA:EGAS00001000978, EGA:EGAS00001002554, FANTOM5_SSTAR:10832-111D4, GDSC:906856, GEO:GSM887006, GEO:GSM888075, GEO:GSM1374475, GEO:GSM1446733, GEO:GSM1669766, IARC_TP53:21331, IARC_TP53:30032, LiGeA:CCLE_554, PharmacDB:EoL1cell_335_2019, PRIDE:PXD030304, Progenetix:CVCL_0258, PubChem_Cell_line:CVCL_0258, RCB:RCB0641, RCB:RCB3679, TKG:TKG 0476, Wikidata:Q54832338

ID: CVCL_0258

Record Creation Time: 20220427T215833+0000

Record Last Update: 20260913T003040+0000

Ratings and Alerts

No rating or validation information has been found for EoL-1.

Warning: Discontinued: RCB; RCB3679

Population: Caucasian., Part of: LL-100 blood cancer cell line panel., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 13 mentions in open access literature.

Listed below are recent publications. The full list is available at [NIF](#) .

Ravazza D, et al. (2026) Quantitative Mass Spectrometry-Based Biodistribution of Monoclonal Antibodies: An Alternative to Radio-Biodistribution. Advanced science (Weinheim, Baden-Wurttemberg, Germany), 13(38), e20265.

Tripathi C, et al. (2026) Nanobody-Engineered CLL-1 CAR T Cells: Optimizing Tumor-Specific Cytotoxicity and Minimizing Off-Tumor Toxicity. Cancer research communications, 6(3), 528.

Bird GH, et al. (2025) A triple-action PROTAC for wild-type p53 cancer therapy. Cell reports. Medicine, 6(12), 102467.

Zhang P, et al. (2025) Systematic evaluation of GAPs and GEFs identifies a targetable dependency for hematopoietic malignancies. Cancer discovery.

Hong J, et al. (2025) PSPC1 exerts an oncogenic role in AML by regulating a leukemic transcription program in cooperation with PU.1. *Cell stem cell*, 32(3), 463.

Schmitt N, et al. (2025) The bispecific innate cell engager AFM28 eliminates CD123+ leukemic stem and progenitor cells in AML and MDS. *Nature communications*, 16(1), 7793.

Fredon M, et al. (2024) Impact of scFv on Functionality and Safety of Third-Generation CD123 CAR T Cells. *Cancer immunology research*, 12(8), 1090.

Blöchl C, et al. (2023) Transcriptionally imprinted glycomic signatures of acute myeloid leukemia. *Cell & bioscience*, 13(1), 31.

Xu C, et al. (2022) A NSD3-targeted PROTAC suppresses NSD3 and cMyc oncogenic nodes in cancer cells. *Cell chemical biology*, 29(3), 386.

Jayavelu AK, et al. (2022) The proteogenomic subtypes of acute myeloid leukemia. *Cancer cell*, 40(3), 301.

Miyamoto R, et al. (2021) HOXA9 promotes MYC-mediated leukemogenesis by maintaining gene expression for multiple anti-apoptotic pathways. *eLife*, 10.

Steinberger J, et al. (2019) Tracing MYC Expression for Small Molecule Discovery. *Cell chemical biology*, 26(5), 699.

Krivtsov AV, et al. (2019) A Menin-MLL Inhibitor Induces Specific Chromatin Changes and Eradicates Disease in Models of MLL-Rearranged Leukemia. *Cancer cell*, 36(6), 660.